# Companion Spine

> Companion Spine is a medical device company building a full continuum of interventional and surgical therapies for back pain caused by degenerative disc disease and lumbar spinal stenosis. Founded in 2020 by the Viscogliosi Brothers, it focuses on posterior dynamic stabilization and motion-preserving implants - such as DIAM, coflex, CoFix, LISA and APERIUS - that treat spine conditions without spinal fusion. With headquarters in New York and Mérignac (Bordeaux), France, the company aims to offer surgeons a single, indication-specific portfolio spanning diagnosis, pain management and outpatient surgery.

- **Founded:** 2020
- **Headquarters:** New York, USA and Mérignac (Bordeaux), France
- **Founders:** Anthony G. Viscogliosi (Executive Chairman, CEO & President), John J. Viscogliosi (Co-Founder / Principal, Viscogliosi Brothers), Marc R. Viscogliosi (Co-Founder / Principal, Viscogliosi Brothers)
- **Team size:** 36
- **Products:** DIAM Spinal Stabilization System, coflex, CoFix, LISA (Lumbar Implant for Stiffness Augmentation), APERIUS
- **Notable:** Secured FDA PMA approval for the DIAM Spinal Stabilization System in December 2025., Earned FDA Breakthrough Device Designation for DIAM in October 2021., Closed a $60.1 million Series A funding round.

## Products & services

- **DIAM Spinal Stabilization System** — Interspinous implant for moderate-to-severe low back pain from degenerative disc disease at a single lumbar level (L2-L5); flagship device, FDA PMA approved December 2025, FDA Breakthrough Device Designation 2021.
- **coflex** — Interlaminar stabilization device used when decompression is required for lumbar spinal stenosis; 90% patient satisfaction and 150+ published papers.
- **CoFix** — Implant for larger decompression cases with significant instability in lumbar spinal stenosis.
- **LISA (Lumbar Implant for Stiffness Augmentation)** — CE-marked posterior dynamic stabilization implant acquired via Backbone SAS (Bordeaux); CE mark received 2018.
- **APERIUS** — Percutaneous interspinous device for early-stage lumbar spinal stenosis.
- **HPS 2.0 / DSS** — Hybrid performance and dynamic stabilization systems for significant instability while preserving adjacent segments.

## Achievements

- Secured FDA PMA approval for the DIAM Spinal Stabilization System in December 2025.
- Earned FDA Breakthrough Device Designation for DIAM in October 2021.
- Closed a $60.1 million Series A funding round.
- Acquired Backbone SAS (Bordeaux) in January 2023, adding the CE-marked LISA implant.
- Acquired Paradigm Spine GmbH and the coflex/CoFix implants from Xtant Medical in 2025, assembling the industry's most comprehensive posterior dynamic stabilization portfolio.

## Latest updates

- **2025-12** — FDA granted Premarket Approval (PMA) for the DIAM Spinal Stabilization System to treat low back pain from degenerative disc disease at a single lumbar level.
- **2025-07** — Announced definitive agreement to acquire Paradigm Spine GmbH and the coflex and CoFix implants from Xtant Medical; acquisition subsequently completed.
- **2025-04** — Anthony G. Viscogliosi appointed CEO, combining the role with Executive Chairman.
- **2023-03** — Series A funding round closed at $60.1 million.
- **2023-01** — Acquired Backbone SAS of Bordeaux, adding the LISA implant to the portfolio.

## Links

- Website: https://companion-spine.com
- LinkedIn: http://www.linkedin.com/company/companion-spine

---

Profile page: https://yespress.io/companion-spine
Published by YesPress — https://yespress.io
Last updated: 2026-07-21